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Despite optimal anti-inflammatory treatment, most asth-
matics experience the need for bronchodilator drugs in
order to relieve acute bronchospasms. Moreover, regular
use of one or more bronchodilator drugs in combination
with anti-inflammatory therapy is part of the therapeutic
strategy against asthma (1). Bronchodilators can be divided
into two groups depending on the pharmacological
mechanism responsible for their relaxant activity. The first
group consists of drugs which block the eect of contractile
mediators on airway smooth muscle either as selective
receptor antagonists or through inhibition of mediator
biosynthesis and/or release. Mediators of asthmatic airway
smooth muscle contraction have been discussed in the first
part of the review. Anticholinergics and leukotriene
modifiers [leukotriene receptor antagonists (e.g. zafirlukast
and montelukast) and inhibtors of 5-lipoxygenase (e.g.
zileuton)] are at present the only drugs in clinical use for
asthma. The second group of airway smooth muscle
relaxants comprises drugs which act as functional antago-
nists to produce airway smooth muscle relaxation regard-
less of the type of contractile mediator inducing airway
tone. This relaxation is achieved through many dierent
cellular pathways which ultimately reduce intracellular
concentration of free Ca2+-ions ([Ca2+]i) and/or aect
Ca2+-sensitivity of the contractile proteins (Fig. 1) (2).
However, four central cellular mechanisms form the basis
for a subdivision of directly acting airway smooth muscle
relaxants: stimulation of a cyclic nucleotide second
messenger system, via either: (a) cyclic 3’,5’-adenosine-
monophosphate (c-AMP); (b) cyclic 3’,5’-guanosine- mono-
phosphate (c-GMP); (c) inhibition of cyclic nucleotide
breakdown; or (d) modulation of cell membrane ion
channel activity.
This review deals with the cellular mechanisms involved
in the relaxant action of directly acting airway smooth
muscle relaxants. Furthermore, the clinical usefulness ofReceived 13 August 1999 accepted in revised form 28 October
1999.
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will be discussed.
b2-Adrenoceptor agonists
Binding of agonists to 2-adrenoceptors results in activa-
tion of the receptor associated G-protein (Gs). Guanosine-
triphosphate (GTP) binds to the  subunit of the
heterotrimeric G-protein complex, resulting in a dissocia-
tion of the -(GTP) and  subunits (Fig. 2). The  subunit
binds to and activates the enzyme adenylate cyclase
catalysing the conversion of intracellular ATP to cyclic
AMP (c-AMP) which in turn activates the c-AMP
dependent protein kinase (protein kinase A; PKA). PKA
phosphorylates many dierent key proteins including
myosin light chain kinase (MLCK), thereby modifying
their function, and this ultimately leads to airway smooth
muscle relaxation. Besides this well established pathway for
airway smooth muscle relaxation, other cellular mechan-
isms involved in the action of 2-adrenoceptor agonists
have been identified. These mechanisms include activation
of the c-GMP dependent protein kinase (protein kinase G;
PKG) by increased concentrations of c-AMP and smooth
muscle hyperpolarization (3,4). Stimulation of isolated
guinea-pig tracheal smooth muscle with 2-adrenoceptor
agonists results in suppression of slow wave activity and
membrane hyperpolarization accompanied by relaxation
(5,6). Maximal relaxant concentrations of isoprenaline
changes the resting membrane potential close to the K+
equilibrium potential, indicating that opening of membrane
K+ channels rather than Cl7 channels are responsible for
the hyperpolarization (5). Although many dierent K+
channels are found in airway smooth muscle (see review
part I), patch-clamp studies have demonstrated that open-
ing of BKCa is responsible for the hyperpolarization
induced by 2-adrenoceptor agonists and that this activa-
tion is obtained through phosphorylation dependent (PKA
and PKG) (7) as well as independent (G-protein coupled)
(8,9) pathways.
The functional importance of K+ channel opening to
airway smooth muscle relaxation produced by 2-adreno-
ceptor agonists is still controversial. Pre-treatment with
selective blockers (charybdotoxin and iberiotoxin) of the
large conductance Ca2+-activated K+ channel (BKCa)# 2000 HARCOURT PUBLISHERS LTD
FIG 1. Main mechanisms involved in airway smooth muscle relaxation: (i) increase in intracellular c-GMP through
stimulation of either the soluble form of guanylate cyclase (GC) by nitric oxide (NO) or the particulate form of GC by means
of specific receptors; (ii) increase in intracellular c-AMP through stimulation of adenylate cyclase (AC) by means of specific
receptors; (iii) plasmalemmal hyperpolarization through opening of ATP-sensitive K+ channels (KATP); (iv) inhibition of
Ca2+-influx through dihydropyridine-sensitive voltage-operated Ca2+ channels (VOC); and (v) inhibition of c-AMP and/or
c-GMP breakdown through selective or non-selective phosphodiesterase (PDE) isoenzyme inhibition. BKCa: large
conductance calcium-activated K+ channel; PKA: protein kinase A; PKG: protein kinase G; PLC: phospholipase C:
MLCK: myosin light chain kinase; SR: sacroplasmic reticulum: inhibition : activation/stimulation; . inhibition.
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adrenoceptor agonists in isolated guinea-pig trachea
(10,11). This eect could, however, simply be functional
antagonism since addition of iberiotoxin to isolated guinea-
pig trachea increases both basal (11) and agonist induced
(12) tone. Elevation of tone is most likely mediated through
membrane depolarization and increased Ca2+ influx
through voltage operated calcium channels (VOC) which
is supported by the observation that nifedipine obliterates
the antagonistic interaction between salbutamol and
charybdotoxin in isolated guinea-pig trachea (13). Contrary
to this, neither the relaxant eect of cromakalim [opener of
the ATP-sensitive K+ channel (KATP)] (10,11) nor the
eects of levcromakalim and the dihydropyridine Ca2+
channel blocker isradipine were antagonized by BKCa7
blockade as should be expected for functional antagonism
(12). In isolated human bronchi charybdotoxin does not
increase tone (14,15), but has been reported either to be
with (14) or without (15) antagonistic eects against
isoprenaline induced relaxations. In conclusion, present
evidence supports the opinion that opening of BKCa has a
supportive rather than an essential role in airway smoothmuscle relaxation induced by 2-adrenoceptor agonists
(16).
In addition to membrane hyperpolarization, other
cellular mechanisms contribute to a reduction in [Ca2+]i
and thereby relaxation. These mechanisms include: (a)
inhibition of agonist induced Ca2+ mobilization through
inhibition of phospholipase C (PLC) (cf. Fig. 1) (17); (b)
augmentation of Na+–Ca2+ exchange through stimulation
of Na+–K+-ATPase (18); (c) increased sarcoplasmic Ca2+
uptake and (d) decreased Ca2+ sensitivity of the contractile
proteins (4).
Repeated and/or high-dose exposure of most membrane-
associated receptor–eector systems to agonists results in a
decline in function despite continued presence of agonist.
This phenomenon, termed desensitization, is also observed
with 2-adrenoceptors and involves cellular processes such
as uncoupling of the 2-adrenoceptor from its G-protein,
sequestration of receptors to intracellular compartments
and downregulation of receptor number through decreased
receptor-messenger-RNA transcription (19,20). 2-adreno-
ceptor uncoupling is initiated by phosphorylation of the
receptor by two dierent kinases: PKA and a c-AMP
FIG 2. 2-Adrenoceptor agonist induced activation of adenylate cyclase. Binding of a selective agonist to the extracellular
domains of the seven transmembrane 2-adrenoceptor (2-AR) results in binding of guanosine-triphosphate (GTP) to the -
subunit (s) of the stimulatory heterotrimeric G-protein (Gs). This in turn leads to dissociation of the s- and -subunits
and subsequently activation of the adenylate cyclase (AC), thereby increasing the intracellular conversion of adenosine
triphosphate (ATP) to cyclic 3’,5’-adenosine monophosphate (c-AMP). G-protein activation is terminated spontaneously
due to the intrinsic GTPase activity of the -subunit dephosphorylating GTP back into guanosine-monophosphate.
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(21). Increased intracellular concentrations of c-AMP is
followed by activation of PKA and phosphorylation of 2-
adrenoceptors regardless of receptor occupancy, which
means that any substance acting through elevation of
intracellular c-AMP can lead to desensitization of 2-
adrenoceptors (heterologous desensitization) (19). In addi-
tion to this, stimulation of 2-adrenoceptors with high
concentrations of agonist does not only lead to non-specific
receptor phosphorylation by PKA, but also to a specific
phosphorylation of the occupied receptors by -ARK
(19,21).
The introduction of selective 2-adrenoceptor agonists in
the 1960s revolutionised the pharmacotherapy of asthma,
and these drugs are still the most widely prescribed
bronchodilators in western countries (22). The so called
short-acting (4–6) 2-adrenoceptor agonists (e.g. terbuta-
line, salbutamol and fenoterol) are potent bronchodilators
producing rapid symptomatic relief of acute bronchos-
pasms and oer protection against a variety of broncho-
constrictor stimuli such as exercise and inhalation ofallergen (20,23). The newer long-acting (8–12) 2-adreno-
ceptor agonists (e.g. salmeterol and formoterol) seem to
improve symptomatic control of asthma compared to
regular use of short-acting 2-adrenoceptor agonist and
provide an alternative to these drugs with regard to
protection against bronchoconstriction (e.g. nocturnal
asthma) (20,24). However, the frequent use of regular
dosing (e.g. four times daily) of short-acting 2-adrenocep-
tor agonists and the introduction of long-acting equivalents
have raised the question of 2-adrenoceptor desensitization
and its clinical consequences. Regular use of a 2-
adrenoceptor agonist (either short- or long-acting) results
over a period of weeks in a small reduction in duration, but
not in magnitude, of the acute bronchodilator response, but
this is generally believed to be without clinical significance
(20,25). Moreover, tolerance develops to the protective
eects of both long- and short-acting 2-adrenoceptor
agonists against a number of bronchoconstrictor stimuli
(20,25). Although this increased bronchial responsiveness
is statistically significant, it only equals the normal
biological variability in bronchial reactivity and the clinical
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eects of 2-adrenoceptor agonists have not been fully
settled (25,26). An increased number of asthma deaths have
been linked to the regular use of high-dose formulations of
the non-selective -agonist isoprenaline as well as the full
2-agonist fenoterol (27). This is probably caused by an
increased number of systemic (e.g. cardiac and metabolic)
side-eects with these drugs as observed with fenoterol in
comparison with other short-acting 2-agonists (28–30),
especially when used in doses higher than 200 g (29).
Moreover, asthma deaths have neither been directly linked
to 2-adrenoceptor desensitization nor to the regular use of
terbutaline or salbutamol (27). With regard to the regular
use of dierent long-acting 2-agonists, data on dierences
in systemic side-eects and a possible link to increased
numbers of asthma deaths are sparse at the moment
(27,31). Despite these unresolved questions, it is generally
accepted that 2-adrenoceptor agonists remain the most
important bronchodilator drugs currently available,
and that these drugs must be regarded as safe, at least
when used in accordance with current international guide-
lines (1).
Vasoactive intestinal peptide
Vasoactive intestinal peptide (VIP) is a 28 amino-acid
peptide recognized as a neuropeptide with a wide anato-
mical distribution, including the lungs (32). In the airways,
VIP-containing neurons are found in the tracheobronchial
smooth muscle layer, around submucosal glands, in the
lamina propria and in the walls of airway vasculature
(32,33). VIP is colocalized with other neuropeptides and
neurotransmitters, in particular substance P, acetylcholine,
noradrenaline and nitric oxide (33,34).
Inhalation or infusion of VIP have only limited
bronchodilator activity in asthmatic subjects but protect
against histamine-induced bronchospasms (35–37). VIP
completely relaxes isolated rings of guinea-pig trachea
contracted by histamine and compared to salbutamol or
terbutaline it is two and ten times as potent, respectively
(12). VIP is degraded by proteases mainly located in the
airway epithelium, and inhibition of these enzymes either
by drugs or epithelial removal potentiates the relaxant
activity of VIP in vitro (38,39). Moreover, rapid degrada-
tion of inhaled or infused VIP could be responsible for the
limited bronchodilator eect observed in vivo. VIP-induced
relaxation of airway smooth muscle is mediated through
binding at specific receptors coupled to the adenylate
cyclase-stimulating G-protein Gs (40) followed by elevation
of intracellular c-AMP (41). A study comparing the eect
of phosphodiesterase inhibitors on the relaxant action of
VIP and two other c-AMP forming drugs (isoprenaline and
PGE2) in guinea-pig trachea suggests that cellular mechan-
isms in addition to elevation of c-AMP may underlie
relaxations induced by VIP compared to those induced by
isoprenaline and PGE2 (42). These additional mechanisms
seem at least to include stimulation of the Na+–K+-
ATPase (43) and activation of BKCa channels (12), whereasopening of KATP channels as in vascular smooth muscle
cells (44) seems unlikely (12).
The extensive distribution within the airways of neurons
containing a potent smooth muscle relaxant such as VIP
raises the question as to whether a decreased biological
activity of such substance (i.e. deficient synthesis, impaired
receptor interaction or increased degradation) could con-
tribute to the pathophysiology of asthma and other airway
diseases (33). Ollerenshaw et al. (45) observed a complete
loss of VIP-containing neurons in lungs from asthmatics,
and decreased levels of VIP-like immunoreactivity have
been detected in patients admitted to hospital with
exacerbations of asthma (46). On the contrary, other
authors have reported a normal VIP content in lung
parenchymal tissue from asthmatics (47) and detected
increased plasma-levels of VIP following bronchial provo-
cation with exercise and methacholine in asthmatic children
(48). Based on these observations, it is at present impossible
to determine the involvement of VIP-bioactivity in the
pathophysiology of asthma.
Activators of guanylate cyclase
Guanylate cyclase, the enzyme responsible for the intracel-
lular conversion of guanosine- triphosphate (GTP) to cyclic
3’,5’-guanosine-monophosphate (c-GMP), exists in two
forms: a soluble and a particulate form (2). The soluble
guanylate cyclase is a haem-protein activated by binding of
NO or the nitro-group in nitrovasodilators to the Fe2+-
group, whereas particulate guanylate cyclase is a mem-
brane-bound enzyme (2,49). Particulate guanylate cyclase is
an integrated part of the intracellular domain of the atrial
natriuretic peptide (ANP) -receptor protein and therefor G-
proteins are not involved in this signal-transduction path-
way (49,50). Activation of either forms of guanylate cyclase
increases the intracellular concentration of c-GMP and is
associated with airway smooth muscle relaxation (51,52).
Increase in the intracellular concentration of c-GMP
activates the c-GMP-dependent protein kinase (PKG),
which has intracellular actions comparable to those of
PKA, including stimulation of sarcoplasmic Ca2+-uptake
(2) and inhibition of sarcoplasmic Ca2+-release (53).
However, studies with ANP in isolated guinea-pig trachea
(54) and the nitrovasodilators sodium nitroprusside
(SNP), nitroglycerine and S-nitroso-N-acetyl-penicillamine
(SNAP) in canine tracheal smooth muscle (55) suggest that
additional c-GMP independent mechanisms must be
involved in the relaxant action of ANP and SNP.
Involvement of BKCa channel opening in the relaxant
action of SNP have now been demonstrated in guinea-pig
(10,11,56), bovine (57) and porcine (58) airway smooth
muscles. This eect is most likely mediated by PKG (2), but
phosphorylation-independent mechanisms, as for the 2-
adrenoceptor agonists (see above), can at present not be
excluded (59). The relaxant eect of ANP in isolated
guinea-pig trachea also involves activation of BKCa and
possible other K+ channels(12), and the hyperpolarization
produced by this activation seems to account for some of the
observed reduction in [Ca2+]i following ANP-stimulation
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tic peptide closely related to ANP) seems to relax bovine
bronchi through mechanisms involving both KATP and
small-conductance Ca2+-activated K+ channels (SKCa) but
not BKCa (61), and further studies into the cellular
mechanisms involved in ANP-induced airway smooth
muscle relaxation are needed.
NO is produced by many dierent cells found in the
airways, including epithelial and endothelial cells, macro-
phages and non-adrenergic non-cholinergic (NANC)
nerves. NO is formed during enzymatically conversion of
L-arginine to L-citrulline catalysed by the enzyme NO-
synthetase (NOS) (62). NOS exists in many dierent
isoforms classified as either constitutive (c-NOS; Ca2+-
dependent) or inducible (i-NOS; Ca2+-independent), and
these isoforms can be further named according to their
localization (63). Low concentrations of NO are found in
exhaled air from normal individuals and, although most of
this originates from the nose and paranasal sinuses,
endogenous NO could be a regulator of normal pulmonary
function (64). Increased concentrations of exhaled NO are
found in asthmatic patients and is regarded as a marker of
airway inflammation (64). NO produced in asthmatic
airways increases bronchial blood flow and plasma exuda-
tion and high local concentrations may have cytotoxic
eects on the airway epithelium resulting in epithelial
destruction (65). Moreover, NO may play an important
role in establishing the asthmatic inflammation character-
ized by eosinophils and mast cells through a regulatory
eect on T-cell subtypes (65).
Inhaled NO and NO-donors (mainly nitroglycerine) have
been investigated as potential therapeutics against dierent
pathological pulmonary conditions, but studies with regard
to bronchial asthma have in general been disappointing.
NO donors possess only limited bronchodilator eect in
patients with mild to moderate asthma, and are associated
with significant side-eects such as headaches, symptomatic
hypotension and syncope (63). Inhalation of NO has no
eect on airway tone in healthy subjects, aords weak
protection against methacholine-induced bronchoconstric-
tion, and is a weak bronchodilator in asthmatics but
not in patients with chronic obstructive pulmonary
disease (66,67). Inhalation of NO is at present used
experimentally in patients with ventilation-perfusion mis-
match due to adult respiratory distress syndrome and
could, together with NO-donors, be part of the future
therapy in patients with this syndrome and other pulmon-
ary vascular conditions such as pulmonary hypertension
(68).
Reduced biological activity of endogenous ANP is not
believed to be involved in asthma pathophysiology, but
exogenous ANP has been investigated as a bronchodilator
substance. Infusion of ANP produces a bronchodilator
response equivalent to salbutamol but of shorter duration
(69), and protects against bronchospasms induced by
histamine (70). Inhalation of ANP (1 mg) protects against
methacholine-induced bronchospasms (71), whereas higher
doses (5 mg) are needed to produce bronchodilation in
asthmatics (72). Although no side-eects were reported in
these studies, neither infused nor inhaled ANP seem to oerany additional eect as an anti-asthmatic compared to
current therapy.
Phosphodiesterase inhibitors
The enzyme phosphodiesterase (PDE) is responsible for the
degradation of intracellular cyclic nucleotides (mainly c-
AMP and c-GMP) by hydrolytic cleavage of their 3’-
phosphoester bond. At least seven dierent PDE isoen-
zymes (PDE I–VII) have at present been recognized, and
many of these are found in several isoforms (2,73). Five of
these PDE isoenzymes (PDE I–V) have been identified in
human (74,75) and guinea-pig (76) airway smooth muscle.
Inhibition of PDE isoenzymes either with isoenzyme-
selective PDE-inhibitors or non-selective drugs (e.g. theo-
phylline), is thought to increase the intracellular concentra-
tion of cyclic nucleotides, thereby producing airway smooth
muscle relaxation through mechanisms almost equivalent
to 2- adrenoceptor agonists and NO-donors (cf. Fig. 1).
However, studies with both selective and non-selective
drugs have revealed that low, moderately relaxant concen-
trations of these drugs are not accompanied by significant
elevation of cyclic nucleotide concentrations, whereas
higher fully relaxant concentrations are (77,78). This could
indicate that cellular mechanisms in addition to the inhi-
bition of PDE isoenzymes are responsible for the relaxant
action of these drugs. Theophylline reverses spontaneous
and agonist-induced tone of isolated guinea-pig trachea
accompanied by inhibition of electrical slow waves and
hyperpolarization (79). Furthermore, pre-treatment of
carbacholine-contracted isolated guinea-pig tracheal pre-
parations with charybdotoxin (180 nM) caused a 7.6 times
rightward displacement of the concentrations-relaxation
curve for theophylline (10), indicating that opening of BKCa
channels are involved in the relaxant action of this drug.
The possible involvement of BKCa and other K
+ channels
in the relaxant action of isoenzyme-selective PDE-inhibi-
tors has not yet been reported.
The functional importance of the dierent PDE iso-
enzymes found in airway smooth muscle with regard to
airway tone have been investigated by means of isoenzyme-
selective PDE- inhibitors. These studies have demonstrated
a central role for PDE IV, and to some extent for PDE III
and V, in both human (75,80) and guinea-pig (76,81)
airways. Both PDE III and PDE IV are responsible for the
degradation of c-AMP, but PDE III has a 20 times lower
Km-value for c-AMP than PDE IV (73) and experimental
evidence supports the suggestion that PDE III accounts for
the basal turnover of c-AMP whereas PDE IV is
functionally linked to degradation of c-AMP produced in
response to exogenous stimuli (78,81,82,83).
Inhibitors of PDE IV have not only attracted interest as
possible bronchodilators, but also as anti-inflammatory
agents (84,85). These drugs have been investigated in
animal models of dierent inflammatory conditions such
as asthma, acute respiratory distress syndrome, septic shock
and multiple sclerosis, and have generally proved to be
eective (85). Moreover, recent studies with theophylline
have indicated an anti-inflammatory action of this classical
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mended for bronchodilation (86,87). Despite this, only
limited information about the eect of isoenzyme-selective
PDE-inhibitors in humans are available at the moment,
implying a restricted clinical usefulness due to central
nervous system side-eects (73,88).
Modulators of transmembrane
ion-fluxes
Among the many dierent ion channels located in smooth
muscle membranes, voltage-operated Ca2+ channels (VOC)
and ATP-sensitive K+ channels (KATP) have in particular
attracted interest as targets for drug therapy. The introduc-
tion of dihydropyridines and related drugs (Ca2+ channel
blockers) in the treatment of hypertension and myocardial
ischaemia was followed by many studies of the possible
usefulness of these drugs as airway smooth muscle
relaxants. In vitro Ca2+ channel blockers relax airway
smooth muscle preparations contracted by a variety of
stimuli, but are approximately 1006 more potent against
contraction induced by depolarization (e.g. high extracel-
lular concentrations of K+) than against those induced by
contractile agonists (89,90). This in accordance with the
observations that intracellular Ca2+ stores and Ca2+-influx
through receptor-operated Ca2+ channels (ROC) rather
than voltage-operated Ca2+ channels (VOC) are involved
in pharmaco-mechanical coupling in airway smooth muscle
(see part I of this review). Many clinical studies have tried
to establish the usefulness of Ca2+ channel blockers in the
treatment of asthma and they have been reviewed elsewhere
(91,92). In general these drugs are without direct bronch-
odilator eect but exhibit an over-additive interaction with
2-adrenoceptor agonists both in vivo and in vitro (93).
Moreover, Ca2+ channel blockers oer a small but
significant protection against bronchoconstrictor stimuli
such as histamine, methacholine, exercise and cold air, with
nifedipine being the most potent. The Ca2+ channel
blockers currently available have no place in the therapy
of asthma but can safely be used to treat cardiovascular
disorders in these patients. Development of drugs which
antagonize Ca2+ influx through ROC could be of interest
as future antiasthmatic drugs.
Cromakalim (BRL 34915), its active l-enantiomer
levcromakalim (lemakalim; BRL 38227) and pinacidil
belong to a group of drugs collectively known as K
channel openers. In guinea-pig trachea these drugs suppress
spontaneous tone and produce 75–100% relaxation of
preparations contracted by agonists such as histamine,
carbacholine and PGF2 (94–97). Moreover, these drugs
suppress airway smooth muscle tone induced by moderately
low extracelular concentrations of K+ (540 mM) but are
without eect against contractions induced by higher
concentrations (95). This finding, together with the
observation that the relaxant eect is accompanied by
cellular hyperpolarization and increased eux of 86Rb+
(marker for K+) (95,96), indicates that these drugs open
membrane K+ channels. The relaxant eect of cromakalimis neither inhibited by apamin (95) nor iberiotoxin (11,12),
but is antagonized by glibenclamide (98,99) identifying
KATP as the cellular target for these drugs. The hyperpo-
larization induced by K+ channel openers reduces the
likelihood of Ca2+ influx through VOCs, and K+ channel
openers should in this way produce airway smooth muscle
relaxation through cellular mechanisms comparable to
Ca2+ channel blockers. However, levcromakalim induces
an additional relaxant response in airway smooth muscle
preparations maximally relaxed by verapamil (100), sug-
gesting that additional cellular mechanisms must be
involved in the relaxant eect of K+ channel openers.
These drugs have minimal eect on cyclic nucleotide
content and phosphodiesterase activity in airway smooth
muscle cells (96) and seem not to alter the Ca2+-sensitivity
of the contractile proteins (95). Closure of VOCs insensitive
to dihydropyridines (16), inhibition of intracellular Ca2+
sequestration (101) and mechanisms involving increased
epithelial NO synthesis (102) have all been suggested as
possible cellular processes involved in the relaxant action of
K+ channel openers, and need further studies.
Clinical studies with K+ channel openers are very
limited. Cromakalim given orally protects against noctur-
nal asthma (103), whereas a single oral dose of levcroma-
kalim has no bronchodilator eect and aords no
protection against histamine-induced bronchospasms
(104). Similar negative results have been obtained with
inhalation of bimakalim (EMD 52692) (105). Although
animal studies suggest that openers of KATP would be
eective in the treatment of airway hyperreactivity (106),
convincing human data are at present lacking.
Concluding remarks
Although they have been used for more than 30 years, 2-
adrenoceptor agonists are still the most widely used airway
smooth muscle relaxant in the pharmacotherapy of asthma.
During the years of their use increasing knowledge with
regard to the cellular mechanisms involved in their relaxant
action has accumulated, and thereby contributed to our
understanding of the regulation of airway smooth muscle
tone. Apart from theophylline, drugs acting through
cellular pathways other than 2-adrenoceptor stimulation
have until now shown limited clinical usefulness. Despite
that, the cellular mechanisms discussed are potential targets
for future bronchodilators.
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